Atom Bioscience, a leading biotechnology company specializing in innovative therapies for inflammatory and metabolic diseases, has recently commenced the recruitment of patients in the United States for a groundbreaking Phase 2b/3 clinical trial. The study focuses on evaluating the efficacy and safety of ABP-671, an orally administered URAT1 inhibitor, as a potential treatment for chronic gout, a prevalent form of inflammatory arthritis.
With 36 sites identified across 17 states, this multicenter, double-blind clinical trial aims to enroll a total of 580 patients worldwide. The trial consists of two parts. Part 1 concentrates on assessing the safety and efficacy of ABP-671 at various doses and regimens, comparing it to either a placebo or allopurinol, the current standard of care for managing gout. Part 2 of the study will then further evaluate selected dosing regimens of ABP-671 from Part 1 against a placebo in patients who were not enrolled during the initial phase.
Gout, characterized by long-term hyperuricemia, affects individuals with excessive concentrations of serum uric acid. With levels greater than 7 mg/dL (420 μmol/L), gout poses a significant burden on an individual’s quality of life and can even increase the risk of sudden cardiac death. Current treatment options for chronic gout exhibit limited efficacy and potential safety concerns like kidney failure, sudden cardiac death, and severe liver toxicity.
Atom Bioscience, with its strong focus on developing best-in-class small molecule therapeutics, strives to bring about a revolution in the treatment of inflammatory and metabolic diseases. ABP-671, the company’s flagship product, holds great promise for chronic gout patients and is currently in clinical development. Additionally, Atom Bioscience’s pipeline includes ABP-745, another small molecule that has shown promising outcomes in preclinical anti-inflammation studies and is now entering phase 1 of clinical trials.
To learn more about Atom Bioscience and their clinical trials, visit their website at https://www.atombp.com or atombp.us. For specific information on the current clinical trial or to inquire about participation, please visit https://studykik.com/study-page/gout-16533?utm_source=Opus&utm_medium=Digital. For media inquiries, please contact Daniel Eramian at Opus Biotech Communications via http://opusbiotech.com/ or call 425-306-8716. For business development opportunities, reach out to Roy J. Wu, Sr. Vice President, Business Development at Atom Bioscience and Pharmaceutical Co., Ltd, via email at [email protected].
Source: [Businesswire](https://www.businesswire.com/news/home/20240424464448/en/)
Atom Bioscience’s initiation of a clinical trial for their URAT1 inhibitor, ABP-671, as a potential treatment for chronic gout marks a significant development in the field of inflammatory arthritis. Gout is a prevalent form of inflammatory arthritis that affects individuals with high levels of serum uric acid, leading to decreased quality of life and potential risks such as sudden cardiac death.
The Phase 2b/3 clinical trial, which has identified 36 sites across 17 states in the United States, aims to enroll a total of 580 patients globally. This multicenter, double-blind study will be conducted in two parts. Part 1 will evaluate the safety and efficacy of ABP-671 at different doses and regimens, comparing it against a placebo or allopurinol, the current standard of care for gout management. Part 2 will subsequently assess selected dosing regimens of ABP-671 against a placebo in patients who were not initially enrolled.
Currently, treatment options for chronic gout have limited effectiveness and may pose safety concerns, including kidney failure, sudden cardiac death, and severe liver toxicity. Atom Bioscience, with its focus on developing innovative small molecule therapeutics, aims to address these limitations and revolutionize the treatment of inflammatory and metabolic diseases. ABP-671, their flagship product, holds great promise for chronic gout patients and is currently in clinical development. Additionally, Atom Bioscience’s pipeline includes ABP-745, another small molecule undergoing phase 1 clinical trials after showing promising results in preclinical anti-inflammation studies.
As Atom Bioscience continues its clinical trials, they encourage those interested in learning more or participating in the current trial to visit their website at [Atom Bioscience](https://www.atombp.com) or [Atom Bioscience US](https://atombp.us). For more information on the specific clinical trial or inquiries about participation, individuals can visit [Studykik](https://studykik.com/study-page/gout-16533?utm_source=Opus&utm_medium=Digital). Media inquiries can be directed to Daniel Eramian at Opus Biotech Communications via [Opus Biotech Communications](http://opusbiotech.com/) or by calling 425-306-8716. For business development opportunities, interested parties can contact Roy J. Wu, Sr. Vice President, Business Development at Atom Bioscience and Pharmaceutical Co., Ltd, via email at [email protected].
It is worth noting that although ABP-671 shows promising potential as a treatment for chronic gout, the results of the clinical trial are still pending. Rigorous testing and regulatory approvals are necessary before it can be made widely available. Additionally, the success of ABP-671 may face challenges such as competition from existing treatments and potential unforeseen side effects. Monitoring the progress of Atom Bioscience’s clinical trials and subsequent developments in the field of gout treatment will provide insight into the future of managing this prevalent form of inflammatory arthritis.